Uncategorized

Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company – no impact on the consolidated financials

Hansa Biopharma AB announces that, in accordance with chapter 4, 6§ of the Swedish Annual Accounts Act and RFR 2, it has elected to recognize a write-up of SEK 1.430 billion in intangible assets in the statutory financial statements of the parent company Hansa Biopharma AB.

Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company – no impact on the consolidated financials Read More »

Janssen Announces Positive Topline Results for JNJ-2113–a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis.1 The trial achieved all primary and secondary efficacy endpoints.

Janssen Announces Positive Topline Results for JNJ-2113–a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis Read More »

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics, Inc. announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor antagonist JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of Dermatology in Singapore.

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis Read More »

Scroll to Top